Primary study · included by 1 review

Melis 2023

ProbableThe reviews cited this study without a PMID, DOI or NCT, so it is matched by first author and year. Two different studies by the same author in the same year could be merged here.

Included by

Adherence to oral antineoplastic agents, an overview and meta-analysis.

Non-Cochrane · prevalence · 2026 · cited as Melis 2023 · Table 3; Figure 3

Outcome this study informs	Pooled effect	Evidence	Certainty
Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) Adherence measured objectively (MEMS, MPR or PDC) · Study durations varied	Pooled proportion (random-effects, logit) 0.71 [0.63, 0.78]	20 studies · 31230 participants	GRADE not reported

1 including review in total.